Chapter 38
Liver Tumors in Special Populations
Tadahiro Uemura MD,
Akhtar Khan MD, FACS,
Zakiyah Kadry MD, FACS,
Tadahiro Uemura MD
Assistant Professor of Surgery
Division of Transplantation, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Search for more papers by this authorAkhtar Khan MD, FACS
Assistant Professor of Surgery
Division of Transplantation, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Search for more papers by this authorZakiyah Kadry MD, FACS
Professor of Surgery
Division of Transplantation, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Search for more papers by this authorTadahiro Uemura MD,
Akhtar Khan MD, FACS,
Zakiyah Kadry MD, FACS,
Tadahiro Uemura MD
Assistant Professor of Surgery
Division of Transplantation, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Search for more papers by this authorAkhtar Khan MD, FACS
Assistant Professor of Surgery
Division of Transplantation, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Search for more papers by this authorZakiyah Kadry MD, FACS
Professor of Surgery
Division of Transplantation, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Liver tumors in nonalcoholic s teatohepatitis
-
Liver tumors in high cardiovascular risk patients: cardiacs tratification for hepatic resection
-
Hepatic resection in elderly patients
-
Hepatic tumors in immunosuppressed patients
-
Liver tumors during pregnancy
-
Self-assessment questions
-
References
-
Self-assessment answers
References
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–8.
- Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (2 Suppl 1 ): S99–112.
- Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682–9.
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
- Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649–57.
- McCullough AJ. The Epidemiology and Risk Factors of NASH. Malden: Blackwell Publishing, 2005.
- Statistics NCF. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–1994. Vital Health Statistics; 1994.
- Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112–17.
- Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142–9.
- Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106–10.
- Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222–6.
- Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513–17.
- Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91–100.
- Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D. Liver damage in obese patients. Obes Surg 2002; 12: 802–4.
- Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135: 48–58.
- Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104: 23–31.
- McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521–33, viii.
- Braillon A, Capron JP, Herve MA, et al. Liver function in moderate obesity–study in 534 moderately obese subjects among 4613 male company employees. Int J Obes 1986; 10: 349–54.
- Nomura F, Ohnishi K, Satomura Y, et al. Liver function in moderate obesity–study in 534 moderately obese subjects among 4613 male company employees. Int J Obesity 1986; 10: 349–54.
- Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349–55.
- Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
- Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042–7.
- Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820–6.
- Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132–8.
- Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74–80.
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113–21.
- Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420–7.
- Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292–8.
- Bell SH, Beringer KC, Detre KM. An update of liver transplantation in the United States: Recipient characteristics and out-comes. In: Cecka JM, TPI, eds. Clinical Transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory, 1996.
- Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363–73.
- Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797–801.
- Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689–92.
- Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127–30.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–19.
- Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664–9.
- Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2007; 19: 827–34.
- Orikasa H, Ohyama R, Tsuka N, Eyden BP, Yamazaki K. Lipidrich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus. J Submicrosc Cytol Pathol 2001; 33: 195–200.
- Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154–60.
- Mori S, Yamasaki T, Sakaida I, et al. Hepatocellular carcinoma with nonalcoholic steatohepatitis. J Gastroenterol 2004; 39: 391–6.
- Cuadrado A, Orive A, Garcia-Suarez C, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg 2005; 15: 442–6.
- Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007; 11: 191–207, x–xi.
- Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.
- Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002; 123: 375–8.
- El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462–7.
- Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096–9.
- Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9.
- Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5: 795–804.
- McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007; 245: 923–30.
- Clavien PA, Selzner M, Rudiger HA, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg 2003; 238: 843–50; discussion 51–2.
- Dimick JB, Wainess RM, Cowan JA, Upchurch GR Jr, Knol JA, Colletti LM. National trends in the use and outcomes of hepatic resection. J Am Coll Surg 2004; 199: 31–8.
- Poon RT, Fan ST, Lo CM, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004; 240: 698–708; discussion 709–10.
- Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397–406; discussion 406–7.
- Virani S, Michaelson JS, Hutter MM, et al. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J Am Coll Surg 2007; 204: 1284–92.
- Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50: 1707–32.
- Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. Am J Cardiol 1991; 68: 973–5.
- Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993; 21: 860–6.
- van Klei WA, Bryson GL, Yang H, Kalkman CJ, Wells GA, Beattie WS. The value of routine preoperative electrocardiography in predicting myocardial infarction after noncardiac surgery. Ann Surg 2007; 246: 165–70.
- Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627–34.
- Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043–9.
- Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997; 127: 313–28.
- Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345: 1677–82.
- Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353: 349–61.
- Poldermans D, Boersma E. Beta-blocker therapy in noncardiac surgery. N Engl J Med 2005; 353: 412–4.
- Feringa HH, Bax JJ, Boersma E, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation 2006; 114 (1 Suppl): I344–9.
- Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006; 48: 964–9.
- Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ 2005; 331: 932.
- Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105: 1260–72; quiz 89–90.
- Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
- Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813–18.
- Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297–301.
- Shimada M, Matsumata T, Maeda T, Itasaka H, Suehiro T, Sugimachi K. Hepatic regeneration following right lobectomy: estimation of regenerative capacity. Surg Today 1994; 24: 44–8.
- Yamamoto K, Takenaka K, Matsumata T, et al. Right hepatic lobectomy in elderly patients with hepatocellular carcinoma. Hepatogastroenterology 1997; 44: 514–18.
- Nomura F, Ohnishi K, Honda M, Satomura Y, Nakai T, Okuda K. Clinical features of hepatocellular carcinoma in the elderly: a study of 91 patients older than 70 years. Br J Cancer 1994; 70: 690–3.
- Fong Y, Brennan MF, Cohen AM, Heffernan N, Freiman A, Blumgart LH. Liver resection in the elderly. Br J Surg 1997; 84: 1386–90.
- Wu CC, Chen JT, Ho WL, et al. Liver resection for hepatocellular carcinoma in octogenarians. Surgery 1999; 125: 332–8.
- Nagano Y, Nojiri K, Matsuo K, et al. The impact of advanced age on hepatic resection of colorectal liver metastases. J Am Coll Surg 2005; 201: 511–16.
- Nagasue N, Chang YC, Takemoto Y, Taniura H, Kohno H, Nakamura T. Liver resection in the aged (seventy years or older) with hepatocellular carcinoma. Surgery 1993; 113: 148–54.
- Lui WY, Chau GY, Wu CW, King KL. Surgical resection of hepatocellular carcinoma in elderly cirrhotic patients. Hepatogastroenterology 1999; 46: 640–5.
- Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in the elderly. J Am Coll Surg 2001; 192: 38–46.
- Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995; 222: 426–34; discussion 34–7.
- Zacharias T, Jaeck D, Oussoultzoglou E, Bachellier P, Weber JC. First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 2004; 240: 858–65.
- Cescon M, Grazi GL, Del Gaudio M, et al. Outcome of right hepatectomies in patients older than 70 years. Arch Surg 2003; 138: 547–52.
- Yeh CN, Jan YY, Chen MF. Hepatectomy for peripheral cholangiocarcinoma in elderly patients. Ann Surg Oncol 2006; 13: 1553–9.
- Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401–10.
- Bonnet F, Balestre E, Thiebaut R, et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis 2006; 42: 411–17.
- Highly active antiretroviral therapy and incidence of cancer in human immunodefi ciency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823–30.
- Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332: 1181–5.
- Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15: 3085–92.
- Hasan FA, Jeffers LJ, Welsh SW, Reddy KR, Schiff ER. Hepatic involvement as the primary manifestation of Kaposi's sarcoma in the acquired immune defi ciency syndrome. Am J Gastroenterol 1989; 84: 1449–51.
- Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94: 1000–6.
- Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006; 24: 3408–14.
- Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16: 683–91.
- Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998; 16: 1112–21.
- Lee FC, Mitsuyasu RT. Chemotherapy of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin N Am 1996; 10: 1051–68.
- Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002; 22: 295–303.
- Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafi a DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24: 1389–94.
- Mossad SB, Tomford JW, Avery RK, Hussein MA, Vaughn KW. Isolated primary hepatic lymphoma in a patient with acquired immunodefi ciency syndrome. Int J Infect Dis 2000; 4: 57–8.
- Ometto L, Menin C, Masiero S, et al. Molecular profi le of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997; 90: 313–22.
- Pelicci PG, Knowles DM, 2nd, Arlin ZA, et al. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune defi ciency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med 1986; 164: 2049–60.
- Scerpella EG, Villareal AA, Casanova PF, Moreno JN. Primary lymphoma of the liver in AIDS. Report of one new case and review of the literature. J Clin Gastroenterol 1996; 22: 51–3.
-
Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodefi ciency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155–63.
10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- Scoazec JY, Degott C, Brousse N, et al. Non-Hodgkin's lymphoma presenting as a primary tumor of the liver: presentation, diagnosis and outcome in eight patients. Hepatology (Baltimore) 1991; 13: 870–5.
- Picciocchi A, Coppola R, Pallavicini F, et al. Major liver resection for non-Hodgkin's lymphoma in an HIV-positive patient: report of a case. Surg Today 1998; 28: 1257–60.
- Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fi brosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47–55.
- Benhamou Y, Bochet M, Di Martino V, et al. Liver fi brosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (Baltimore) 1999; 30: 1054–8.
- Schreibman I, Gaynor JJ, Jayaweera D, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84: 697–705.
- Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47: 527–37.
- Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (Baltimore) 2008; 47: 407–17.
- Penn I. Primary malignancies of the hepato-biliary-pancreatic system in organ allograft recipients. J HBP Surg 1998; 5: 157–64.
- Hanson MN, Morrison VA, Peterson BA, et al. Posttransplant T-cell lymphoproliferative disorders–an aggressive, late complication of solid-organ transplantation. Blood 1996; 88: 3626–33.
- Capello D, Cerri M, Muti G, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 2003; 102: 3775–85.
- Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173–92.
- Caillard S, Lelong C, Pessione F, Moulin B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735–42.
- Cockfi eld SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56: 88–96.
- Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103–8.
- Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69: 827–33.
- Allen U, Hebert D, Moore D, Dror Y, Wasfy S. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multicentre experience. Pediatr Transplant 2001; 5: 198–203.
- Nuckols JD, Baron PW, Stenzel TT, et al. The pathology of liverlocalized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol 2000; 24: 733–41.
- Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001; 3: 88–96.
- Petit B, Le Meur Y, Jaccard A, et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002; 73: 265–71.
- Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748–55.
- Cheung AN, Chan AC, Chung LP, Chan TM, Cheng IK, Chan KW. Post-transplantation lymphoproliferative disorder of donor origin in a sex-mismatched renal allograft as proven by chromosome in situ hybridization. Mod Pathol 1998; 11: 99–102.
- Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076–88.
- Humar A, Hebert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81: 856–61.
- Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569–76.
- Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053–7.
- Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracyclinebased chemotherapy as fi rst-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006; 82: 375–81.
- Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in post-transplant lymphoproliferative disorders with a doseadjusted ACVBP regimen. Br J Haematol 2006; 134: 602–12.
- Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ. Radiofrequency ablation of lymphoma. Blood 2006; 107: 1624–6.
- Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52–61.
- Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629–37.
- Courouce AM, Bouchardeau F, Chauveau P, et al. Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays). Nephrol Dial Transplant 1995; 10: 234–9.
- Othman B, Monem F. Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria. Infection 2001; 29: 262–5.
- Mioli VA, Balestra E, Bibiano L, et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. Nephron 1992; 61: 278–83.
- Teles SA, Martins RM, Gomes SA, et al. Hepatitis B virus transmission in Brazilian hemodialysis units: serological and molecular follow-up. J Med Virol 2002; 68: 41–9.
- Oguchi H, Miyasaka M, Tokunaga S, et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38: 36–43.
- Chan TM, Lok AS, Cheng IK. Hepatitis C infection among dialysis patients: a comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6: 944–7.
- Chen KS, Lo SK, Lee N, Leu ML, Huang CC, Fang KM. Superinfection with hepatitis C virus in hemodialysis patients with hepatitis B surface antigenemia: its prevalence and clinical significance in Taiwan. Nephron 1996; 73: 158–64.
- Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534–40.
- Croitoru A, Schiano TD, Schwartz M, et al. De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci 2006; 51: 1780–2.
- Cheng SB, Yeh DC, Shu KH, et al. Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation. J Surg Oncol 2006; 93: 273–8.
- Chok KS, Lam CM, Li FK, et al. Management of hepatocellular carcinoma in renal transplant recipients. J Surg Oncol 2004; 87: 139–42.
- Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999; 17: 324–31.
- Kita Y, Klintmalm G, Kobayashi S, Yanaga K. Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci 2007; 52: 3392–3.
- Aseni P, Vertemati M, Minola E, et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transpl 2001; 7: 816–23.
- Cattani P, Capuano M, Graffeo R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol 2001; 39: 506–8.
- Chang Y, Moore PS. Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Infect Agents Dis 1996; 5: 215–22.
- Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. Q J Med 2005; 98: 205–14.
- Gheith O, Bakr A, Wafa E, et al. Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient. Clin Exp Nephrol 2007; 11: 251–4.
- Iaria G, Anselmo A, De Luca L, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports. Transplant Proc 2007; 39: 2036–7.
- Di Paolo S, Teutonico A, Ranieri E, Gesualdo L, Schena PF. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am J Kidney Dis 2007; 49: 462–70.
- Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633–7.
- Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl 2005; 11: 1412–16.
- Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451–8; discussion 8–61.
- Heneghan MA, Tuttle-Newhall JE, Suhocki PV, et al. De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am J Transplant 2003; 3: 634–8.
- Storms P, Ramli Y. Cholangiocarcinoma in an immunosuppressed kidney transplant patient. A case report and review of literature. Acta Chirurg Belgica 1990; 90: 24–6.
- Athanassiou AM, Craigo SD. Liver masses in pregnancy. Semin Perinatol 1998; 22: 166–77.
- Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004; 187: 181–91.
- Ochsner JL, Halpert B. Cavernous hemangioma of the liver. Surgery 1958; 43: 577–82.
- Ishak KG, Rabin L. Benign tumors of the liver. Med Clin N Am 1975; 59: 995–1013.
- Itai Y. Liver haemangioma and pregnancy. Lancet 1996; 347: 1693–4.
- Itzchak Y, Adar R, Bogokowski H, Mozes M, Deutsch V. Intrahepatic arterial portal communications: angiographic study. AJR Am J Roentgenol 1974; 121: 384–7.
- Martin B, Roche A, Radice L, Aguilar K, Kraiem C. [Does arterial embolization have a role in the treatment of cavernous hemangioma of the liver in adults?] Presse Med 1986; 15: 1073–6.
- Saegusa T, Ito K, Oba N, et al. Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med (Tokyo) 1995; 34: 207–11.
- Creasy GW, Flickinger F, Kraus RE. Maternal liver hemangioma in pregnancy as an incidental fi nding. Obstet Gynecol 1985; 66 (3 Suppl): 10S–3S.
- Schwartz SI, Husser WC. Cavernous hemangioma of the liver. A single institution report of 16 resections. Ann Surg 1987; 205: 456–65.
- Lee MJ, Saini S, Hamm B, et al. Focal nodular hyperplasia of the liver: MR findings in 35 proved cases. AJR Am J Roentgenol 1991; 156: 317–20.
- Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000; 118: 560–4.
- Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2: 926–9.
- Steinbrecher UP, Lisbona R, Huang SN, Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981; 26: 1045–50.
- Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception 1991; 43: 643–52.
- Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 2005; 7: 186–96.
- Terkivatan T, de Wilt JH, de Man RA, Ijzermans JN. Management of hepatocellular adenoma during pregnancy. Liver 2000; 20: 186–7.
- Terkivatan T, de Wilt JH, de Man RA, van Rijn RR, Tilanus HW, IJzermans JN. Treatment of ruptured hepatocellular adenoma. Br J Surg 2001; 88: 207–9.
- Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC. Selective management of hepatic adenomas. Am Surgeon 1996; 62: 825–9.
- El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35 (5 Suppl 2 ): S72–8.
-
Lau WY, Leung WT, Ho S, et al. Hepatocellular carcinoma during pregnancy and its comparison with other pregnancyassociated malignancies. Cancer 1995; 75: 2669–76.
10.1002/1097-0142(19950601)75:11<2669::AID-CNCR2820751105>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- Shiu W, Dewar G, Leung N, et al. Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases. Oncology 1990; 47: 241–5.
- Erfl ing W. Effect of estrogens on the liver. Case presentation. Gastroenterology 1978; 75: 512.
- Alvarez de la Rosa M, Nicolas-Perez D, Muniz-Montes JR, Trujillo-Carrillo JL. Evolution and management of a hepatocellular carcinoma during pregnancy. J Obstet Gynaecol Res 2006; 32: 437–9.
- Goodman S. Anesthesia for nonobstetric surgery in the pregnant patient. Semin Perinatol 2002; 26: 136–45.
- Fatum M, Rojansky N. Laparoscopic surgery during pregnancy. Obstet Gynecol Surv 2001; 56: 50–9.
- Jabbour N, Brenner M, Gagandeep S, et al. Major hepatobiliary surgery during pregnancy: safety and timing. Am Surgeon 2005; 71: 354–8.
- Campeau L. Letter: Grading of angina pectoris. Circulation 1976; 54: 522–3.
- Brand MI, Saclarides TJ, Dobson HD, Millikan KW. Liver resection for colorectal cancer: liver metastases in the aged. Am Surg 2000; 66: 412–15.
